Dipexium Pharmaceuticals, Inc. (PLXP) Receives Consensus Rating of “Hold” from Analysts
Shares of Dipexium Pharmaceuticals, Inc. (NASDAQ:PLXP) have been given an average broker rating score of 3.00 (Hold) from the one brokers that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating.
Zacks has also assigned Dipexium Pharmaceuticals an industry rank of 124 out of 265 based on the ratings given to related companies.
ILLEGAL ACTIVITY NOTICE: “Dipexium Pharmaceuticals, Inc. (PLXP) Receives Consensus Rating of “Hold” from Analysts” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/07/24/dipexium-pharmaceuticals-inc-plxp-receives-consensus-rating-of-hold-from-analysts.html.
In other Dipexium Pharmaceuticals news, insider Michael J. Valentino purchased 29,091 shares of Dipexium Pharmaceuticals stock in a transaction dated Wednesday, June 14th. The shares were acquired at an average cost of $6.88 per share, with a total value of $200,146.08. Following the completion of the transaction, the insider now owns 122,386 shares in the company, valued at approximately $842,015.68. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO David Emerson Jorden purchased 32,727 shares of Dipexium Pharmaceuticals stock in a transaction dated Wednesday, June 14th. The shares were acquired at an average cost of $6.88 per share, for a total transaction of $225,161.76. Following the completion of the transaction, the chief financial officer now owns 151,913 shares of the company’s stock, valued at approximately $1,045,161.44. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 69,091 shares of company stock worth $475,346. Insiders own 47.70% of the company’s stock.
An institutional investor recently bought a new position in Dipexium Pharmaceuticals stock. Heritage Way Advisors LLC acquired a new position in shares of Dipexium Pharmaceuticals, Inc. (NASDAQ:PLXP) during the second quarter, according to its most recent filing with the SEC. The fund acquired 32,101 shares of the biotechnology company’s stock, valued at approximately $197,000. Heritage Way Advisors LLC owned about 0.37% of Dipexium Pharmaceuticals at the end of the most recent reporting period. Hedge funds and other institutional investors own 39.03% of the company’s stock.
Shares of Dipexium Pharmaceuticals (NASDAQ:PLXP) traded up 1.68% during mid-day trading on Monday, reaching $6.05. The company’s stock had a trading volume of 1,879 shares. The firm’s 50 day moving average is $6.28 and its 200 day moving average is $8.80. The firm’s market cap is $26.52 million. Dipexium Pharmaceuticals has a one year low of $5.60 and a one year high of $142.01.
Dipexium Pharmaceuticals Company Profile
PLx Pharma Inc, formerly Dipexium Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dipexium Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dipexium Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.